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Introduction: Approximately 55,000 women in the United Kingdom are diagnosed with new breast can-
cer annually. Since emerging in December 2019, SARS-CoV-2 (coronavirus disease 2019, COVID-19) has
become a global pandemic, affecting healthcare delivery worldwide. In response to the pandemic, mul-
tiple guidelines were issued to assist with rationalising breast cancer care. The primary aim of the B-
MaP-C study is to audit and describe breast cancer management of patients newly diagnosed with breast
cancer during the COVID-19 pandemic against pre-COVID-19 management practice in the UK. The impli-
cations of changes to management will be determined and the impact of a COVID-19 diagnosis on the
patient’s breast cancer management will be determined.
Methods and analysis: This is a multi-centre collaborative audit of consecutive breast cancer patients
undergoing treatment decisions during the acute and recovery phases of the COVID-19 pandemic. All
patients with newly diagnosed primary breast cancer, whose treatment was decided in a multidisci-
plinary meeting from the 16th March 2020, are eligible for inclusion.
Ethics and dissemination: As this is an audit ethical approval is not required. Each participating centre is
required to register the study locally and obtain local governance approvals prior to commencement of
data collection. Local audit data will be available to individual participating units for governance pur-
poses. The results of the data analysis will be submitted for publication, as well as disseminated via
the ABS newsletter and a webinar. All data will be presented at national and international conferences,
circumstances permitting.
Registration details: Each participating centre received local governance audit registration.
 2020 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Approximately 55 000 women in the United Kingdom are diag-
nosed with new breast cancer each year [1]. Multi-modal treat-
ment involves a combination of surgery and systemic therapy,
which often involve multiple hospital visits or admissions, increas-
ing the potential risk of exposure to COVID-19. The first case of the
novel coronavirus SARS-CoV-2 (coronavirus disease 2019, COVID-
19) was diagnosed in the UK on the 23rd January 2020 [2], with
the first death recorded on the 5th March [3,4]. As of 5th June
2020, COVID-19 has resulted in 6,515,796 confirmed cases and
387,298 deaths worldwide since its emergence in December
2019 [5]. Globally, the COVID-19 pandemic has led to repercus-
sions in healthcare delivery, including alterations in cancer care.
In the UK, the Association of Breast Surgery (ABS) published a guid-
ance statement, outlining the temporary changes required to the
work-up of patients with breast symptoms and the surgical man-
agement of patients with a new diagnosis of breast cancer [6].
The guidelines were intended to help breast units rationalise deliv-
ery of breast services whilst healthcare resources were limited and
when hospitals were considered a high risk environment for many
vulnerable patients.
In summary, the ABS advised the following changes to be imple-
mented [6]:
1. If operating theatre capacity was limited, patients should be
prioritized for surgery in the following order: oestrogen recep-
tor (ER) negative cancers, human epidermal growth factor
receptor 2-positive (HER2+) cancers, pre-menopausal ER+ can-
cers, post-menopausal ER+ cancers, high grade ductal carci-
noma in situ (DCIS), intermediate or low grade DCIS. In case
of insufficient theatre capacity, post-menopausal ER+ patients
could be commenced on endocrine therapy.
2. Neoadjuvant chemotherapy should only to be offered to
patients with inoperable disease and should not be used to
downstage from mastectomy to breast conserving surgery
(BCS) or to perform axillary conservation in patients with ER
or HER2+ disease. This is to avoid a potential delay to definitive
surgical treatment of the primary cancer.
3. All immediate breast reconstruction (IBR) was suspended, with
delayed reconstruction to be offered at a later date once the ser-
vice returned to normal to minimise surgical complexity, length
of stay, complication risks, therefore reducing the risk of devel-
oping COVID-19.
4. Genomic testing on the core biopsy should be considered in all
grade 3 or node positive ER+ patients [6]. Patients with a high
recurrence score should be advised to have surgery as they
would ordinarily need adjuvant chemotherapy.
The Royal College of Radiologists (RCR) produced guidelines on
the rationalisation of radiotherapy (RT) for breast cancer patients
during the pandemic [7] subsequently supported by International
guidelines. These were in part based on the published results of
the Fast Forward trial, which demonstrated non-inferiority for
local recurrence for 5 fractions of adjuvant radiotherapy compared
to the UK standard of care 15 fraction [8,9].
The guidelines recommended the following options be consid-
ered and discussed with the patient for shared decision-making:
Radiotherapy omission for patients over 65 years (or younger
comorbid patients) with invasive breast cancer of 30 mm or less,
provided they fulfilled the following criteria: clear margins, grade
(G) 1–2, ER+, HER2- and node negative commencing endocrine
therapy. RT could be delivered in 5 fractions for node negative dis-
ease. Boost RT could be offered only to patients under 40 years or
those over 40 with high risk of relapse. Nodal RT could be omittedin the following cases: 1) post-menopausal women undergoing
whole breast RT after sentinel lymph node biopsy; 2) primary sur-
gery for T1, ER+, HER2- G1-2 tumours with 1–2 macrometastases
[7].
The guidelines also highlight that pre-operative breast radio-
therapy could be used as an emergency bridging measure in
patients where surgery was postponed during the COVID-19 pan-
demic and further pre-operative systemic therapy was not possi-
ble. These included patients with a new diagnosis of invasive
breast cancer or patients completing neoadjuvant therapy, where
systemic therapy was not appropriate, or patients with disease
progression despite use of systemic therapies [10].
In line with the national guidelines [11], the Cancer Core Europe
(CCE) consortium published general consensus measures on the re-
structuring of service delivery during the COVID-19 pandemic [12].
They recommended to record and analyse the impact of treatment
alterations during the pandemic on the cancer specific patient out-
comes [12]. Pardo et al. published a suggested approach to the
management of breast cancer patients during different stages of
the pandemic, based on their local experience [13]. Several other
publications reported the outcomes of COVID-19 disease in cancer
patients [14–16], although none of these papers focused specifi-
cally on the outcomes of the breast cancer patients [17].1.1. Aims and objectives
The primary aim of the B-MaP-C study is to audit and describe
breast cancer management during the COVID-19 pandemic against
standard pre-COVID-19 management practice. In addition, the
impact of a COVID-19 diagnosis on the patient’s breast cancer
management will be determined.
The short-term audit objectives are to determine the impact of
the COVID-altered management on the patient outcomes,
including:
1. The proportion of patients on ‘bridging’ neoadjuvant endocrine
therapy (NET), who progress or fail to respond to this treatment,
and subsequently require surgery for clinical reasons earlier
than anticipated.
2. The proportion of patients, who would normally be offered IBR,
undergoing simple mastectomy, who then proceed to have a
delayed reconstruction, which could include mixed-methods
analysis of psychological impact.
The long-term aim is to audit outcomes in patients undergoing
COVID-altered treatment. This national cohort of patients can be
interrogated in the future for oncological outcomes, for example:
1. The impact of NET on service provision as surgery is reopened
2. The response to NET, in a cohort of patients who would ordinar-
ily have surgery
3. Impact of COVID-altered management on local and distant
recurrence
2. Methods and analysis
This is a multi-centre collaborative study of consecutive
patients with breast cancer undergoing MDT treatment decisions
during the acute and recovery phases of the COVID-19 pandemic.
The recruitment period is from the 16th March 2020 (commence-
ment of social distancing recommendations in UK) until the local
recommencement of routine breast cancer management as gauged
by the availability of pre-COVID services and facilities are deter-
mined. It is anticipated that most units will resume standard prac-
tice at a similar time point.
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Inclusion criteria
 New diagnosis of non-invasive / invasive primary breast cancer
(pathological classification B5a, B5b, B5c [18])
 AND treatment during the COVID-19 pandemic (from the 16th
March 2020 until the recovery phase of the pandemic is
established)
Exclusion criteria:
 recurrent or metastatic breast cancer
 diagnosis of benign breast disease (i.e. no malignancy found)
 patients undergoing primarily symmetrising and risk-reducing
surgery
 surgery for indeterminate or suspicious (B3/B4) lesions
detected on core biopsy
2.2. Study design
All breast cancer units in the UK and Europe are eligible to par-
ticipate. Study information is available on the website bmapc.org,
which hosts the collaborator recruitment sign-up process. The UK
Association of Breast Surgery has endorsed the study and encour-
aged all members to participate.
This is a multi-centre collaborative audit. Collaborative study
design is a well-tested method of delivery of high-quality cohort
studies in the UK [14,19,20] with the capacity to generate mean-
ingful large scale data with the potential to inform or change clin-
ical practice. There have been several successful trainee
collaborative studies related to breast surgery [21–24].
2.3. Data collection
All eligible consecutive patients will be identified prospectively
by the local participating clinical teams via the documentation
from local multidisciplinary team (MDT) meetings. It is assumed
that standard or COVID-altered treatment pathways for each
patient will be clearly recorded in the MDT records, as per ABS
guidelines. Prospective data entry is preferred, following the MDT
meeting. It is accepted that in some centres, for example with a
high burden of COVID-19 patients, retrospective data collection
will be required.
Data collection will occur in accordance with Caldicott II
principles. All data will be recorded in an anonymised format
using a unique alphanumeric study identification number. A
secure record of NHS numbers and corresponding REDCap ID
will be kept locally to facilitate ‘staged’ data collection and
future outcome studies. No patient identifiable data will be col-
lected or recorded centrally for the purpose of the audit. Study
data will be collected and managed using REDCapTM electronic
data capture tools hosted at The University of Manchester
[25,26]. REDCapTM (Research Electronic Data Capture) is a secure,
web-based software platform designed to support data capture
for research studies, providing 1) an intuitive interface for vali-
dated data capture; 2) audit trails for tracking data manipula-
tion and export procedures; 3) automated export procedures
for seamless data downloads to common statistical packages;
and 4) procedures for data integration and interoperability with
external sources [27].
Data collection will be conducted in three phases (Fig. 1).
1. Phase 1 will register patients to the study, document cancer
TNM stage, and classify the type of treatment received (stan-
dard or COVID-altered).2. Phase 2 will collect the details of patient demographics, imag-
ing, staging, pathology results and the specifics of the COVID-
altered treatment.
3. Phase 3 will collect long-term treatment and outcome data for
specific subsets of patients. This phase will be iteratively devel-
oped depending on the evolution of the pandemic and the sub-
sequent data collected in phases 1 and 2.
For details of the REDCap Sections 1–5 data collection, please
refer to Supplement 1
2.4. Data validation and management
For quality assurance purposes, REDCap’s built-in data quality
rules will be used to find discrepancies and errors in the project
data. In addition, in the lead up to publication, interim analyses
will be performed to look for discrepancies in the data, and if iden-
tified, the study site will be contacted to validate that record. This
is consistent with the quality assurance procedure used in other
large collaborative audit projects [19]; however, rather than select-
ing a random sample to validate, specific cases will be identified.
2.5. Data analysis
The study report will be prepared according to the STROBE
(Strengthening the Reporting of Observational Studies in Epidemi-
ology) reporting guidelines for observational studies [28]. All data
analysis will occur centrally by the B-MAP-C study teamwith input
from a biostatistician. It is anticipated that simple descriptive sum-
mary statistics will be calculated for each outcome. Data will be
tested for normality and differences between groups using
unpaired t-tests, Mann-Whitney U tests and Chi squared tests if
appropriate.
3. Ethics and dissemination
Ethical approval is not required for this cohort study as it was
classified as an audit according to the NHS Health Research
Authority online decision tool http://www.hra-decisiontools.org.
uk/research/. However, each participating centre is required to reg-
ister the study locally and obtain local governance approvals prior
to commencement of data collection. Data collection will be based
on routine clinical data already available to local clinical teams.
Collected data will be compared to established standard breast
cancer management [29] as well as COVID-specific guidelines pub-
lished by the ABS [6] and the RCR [7,10].
Local audit data will be available to individual participating
centres at any given time. Participating centres will have owner-
ship of their own data. Results of data analysis will be submitted
for publication, the ABS newsletter and a webinar. All data will
be presented at national and international conferences, circum-
stances permitting.
4. Discussion
This European study aims to describe the extent of alterations
in the management of breast cancer during the COVID-19 pan-
demic on a patient and population-based level to help us under-
stand the true impact of the pandemic on patient outcomes and
the degree to which breast cancer management has been affected.
This knowledge will assist us with the long-term planning of ser-
vice delivery once routine breast cancer management resumes or
if another pandemic were to occur. In addition, our findings will
be helpful for long-term counselling of patients with breast cancer.
Since the outcomes of our study are likely to evolve depending on
Fig. 1. Phases of data collection.
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the potential findings.
In the UK, the National Institute for Health and Care Excellence
(NICE) guidelines recommend that all women, undergoing a mas-
tectomy, should be offered breast reconstruction, in view of the
potential psychological effects associated with the loss of a breast
[29]. However, the COVID-19 pandemic has led to suspension of
IBR in many countries worldwide due to resource, workforce and
safety concerns [30]. We aim to identify this cohort of women that
did not have IBR as a result of the pandemic and audit patient-
specific outcomes. For example, we could determine the type of
reconstruction performed and the duration of waiting time against
published guidelines [31], as well as assess the impact on patients’
psychological and mental health [32,33].
We will audit the outcomes of neoadjuvant endocrine therapy
(NET) in a real-world setting. Based on the national guidelines, it
is anticipated that significant number of patients with
ER + HER2- cancers will have their surgery deferred to minimise
the risk of COVID-19 transmission as a result of hospital admission
for surgery. There is evidence to suggest that NET may be utilised
in post-menopausal women to facilitate breast conservation in 30–
70% of women requiring mastectomy at baseline [34–36]. There is
also evidence suggesting its clinical equivalence to neoadjuvant
chemotherapy in post-menopausal women with ER positive dis-
ease [34]. The use of NET in pre-menopausal women is less well
established and will be evaluated in this study.
In the long term, we will have the opportunity to assess the
impact of treatment alterations on the rate of disease recurrence
and overall patient survival. If breast cancer outcomes following
altered management are shown to be comparable to standard
treatment, it may prompt future interventional trials.
Finally, we anticipate that the B-MaP-C study will strengthen
the collaborative breast cancer research network and will reinforcemultidisciplinary links with the medical and radiation oncology
research communities, allowing for better collaboration in the
future.5. Study status
Data collection has commenced across the UK and Europe, with
59 UK units and 7 European units registered to participate to date.
Interim analysis for the ‘acute phase’ of COVID-19 is expected to be
undertaken at the end of June 2020.6. Authors’ contributions
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